NCT00883480

Individualized Treatment Based on Epidermal Growth Factor Receptor Mutations and Level of BRCA1 Expression in Advanced Adenocarcinoma

Tratamiento Individualizado en función de Las Mutaciones en EGFR y Del Nivel de expresión de BRCA1 en Pacientes Con Adenocarcinoma de pulmón Avanzado

• Status: Completed
• Phase: N/A
• Study type: Interventional
• Enrollment: 153 (actual)
• Sponsor: Spanish Lung Cancer Group · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This is a pharmacogenic, prospective, and multicenter study in patients with advanced lung adenocarcinoma.

Detailed description

Pharmacogenomic study, prospective, multicenter. Individualized treatment based on EGFR mutations and level of BRCA1 expression in patients with advanced lung adenocarcinoma

Conditions

• Non-small Cell Lung Cancer

Interventions

Type	Name	Description
DRUG	Docetaxel	Docetaxel 75 mg/day 1 x 4 cycles
DRUG	Cisplatin	Docetaxel-Cisplatin 75 mg/day 1 x 4 cycles
DRUG	Gemcitabine	Cisplatin 75 mg/ day 1 x 4 cycles Gemcitabine 1250 mg/ day 1 and 8 x 4 cycles
DRUG	Erlotinib	Erlotinib 150 mg/day x 21 days

Timeline

• Start date: 2005-06-01
• Primary completion: 2008-01-01
• Completion: 2008-11-01
• First posted: 2009-04-17
• Last updated: 2022-06-13

Locations

2 sites across 1 country: Spain